Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: potential role of tannins in cancer chemotherapy.

Doxorubicin, an anthracycline antibiotic, is widely used in the treatment of various solid tumors including breast cancer. However, its use is limited due to a variety of toxicities including cardiotoxicity. The present study aimed to evaluate the effect of tannic acid, a PARG/PARP inhibitor and an antioxidant, on doxorubicin-induced cardiotoxicity in H9c2 embryonic rat heart myoblasts and its anti-cancer activity in MDA-MB-231 human breast cancer cells as well as in DMBA-induced mammary tumor animals. Doxorubicin-induced cardiotoxicity was assessed by measurement of heart weight, plasma LDH level and histopathology. Bcl-2, Bax, PARP-1 and p53 expression were examined by western blotting. Our results show that tannic acid prevents activation of PARP-1, reduces Bax and increases Bcl-2 expression in H9c2 cells, thus, preventing doxorubicin-induced cell death. Further, it reduces the cell viability of MDA-MB-231 breast cancer cells, increases p53 expression in mammary tumors and shows maximum tumor volume reduction, suggesting that tannic acid potentiates the anti-cancer activity of doxorubicin. To the best of our knowledge, this is the first report which shows that tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity both in vitro (H9c2 and MDA-MB-231 cells) as well as in in vivo model of DMBA-induced mammary tumor animals.

[1]  B. Kalyanaraman,et al.  Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes. , 2008, Free radical biology & medicine.

[2]  N. Breusing,et al.  Chromatin repair after oxidative stress: role of PARP-mediated proteasome activation. , 2010, Free radical biology & medicine.

[3]  C. Blomqvist,et al.  The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer , 2009, Acta oncologica.

[4]  K. Yagi,et al.  Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. , 1979, Analytical biochemistry.

[5]  R. Brasseur,et al.  Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. , 1990, Biophysical chemistry.

[6]  O. Straume,et al.  Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors. , 2004, Cancer letters.

[7]  A. Saraste,et al.  Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. , 2000, Cancer research.

[8]  F. Denizot,et al.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.

[9]  M. Hermes-Lima,et al.  The antioxidant effect of tannic acid on the in vitro copper-mediated formation of free radicals. , 2005, Archives of biochemistry and biophysics.

[10]  D. Kabra,et al.  Differential effects of tannic acid on cisplatin induced nephrotoxicity in rats , 2007, FEBS letters.

[11]  K. McKenzie,et al.  Animal models for breast cancer. , 1995, Mutation research.

[12]  S. Menichetti,et al.  Mono‐galloyl glucose derivatives are potent poly(ADP‐ribose) glycohydrolase (PARG) inhibitors and partially reduce PARP‐1‐dependent cell death , 2008, British journal of pharmacology.

[13]  T. Gabryelak,et al.  Interactions of tannic acid and its derivatives (ellagic and gallic acid) with calf thymus DNA and bovine serum albumin using spectroscopic method. , 2006, Journal of photochemistry and photobiology. B, Biology.

[14]  M. Carraway,et al.  The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. , 2007, The Journal of clinical investigation.

[15]  K. Tikoo,et al.  Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats , 2009, BMC Cancer.

[16]  R. Chlebowski.  Adriamycin (doxorubicin) cardiotoxicity: a review. , 1979, The Western journal of medicine.

[17]  W. Shou,et al.  A Mouse Model for Juvenile Doxorubicin-Induced Cardiac Dysfunction , 2008, Pediatric Research.

[18]  R. Swanson,et al.  Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Joy Joseph,et al.  Doxorubicin-induced apoptosis: Implications in cardiotoxicity , 2002, Molecular and Cellular Biochemistry.

[20]  Liu,et al.  Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway , 2009, Circulation.

[21]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[22]  M. Papa,et al.  Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. , 2006, European journal of cancer.

[23]  C. Szabó,et al.  Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. , 2002, The Journal of pharmacology and experimental therapeutics.

[24]  Y. Hiraku,et al.  Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. , 2005, Life sciences.

[25]  J. Baselga,et al.  Targeted therapies in breast cancer: where are we now? , 2008, European journal of cancer.

[26]  T. Gant,et al.  Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation , 2010, PloS one.

[27]  J. Mason,et al.  Anthracycline cardiomyopathy monitored by morphologic changes. , 1978, Cancer treatment reports.

[28]  J. Dingell,et al.  Molecular basis of anthracycline- induced cardiotoxicity , 2007 .

[29]  S. Eksborg,et al.  Protein binding of anthraquinone glycosides, with special reference to adriamycin , 1982, Cancer Chemotherapy and Pharmacology.

[30]  M. Carpenter,et al.  Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats , 2006, Journal of carcinogenesis.

[31]  O. Chassany,et al.  Comparative serum protein binding of anthracycline derivatives , 1996, Cancer Chemotherapy and Pharmacology.

[32]  P. Singal,et al.  Adriamycin cardiomyopathy: pathophysiology and prevention , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  S. Milstien,et al.  Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. , 2007, Cancer research.

[34]  T. Wei,et al.  Antioxidant properties of two gallotannins isolated from the leaves of Pistacia weinmannifolia. , 2005, Biochimica et biophysica acta.

[35]  M. Jacobson,et al.  Identification of an inhibitor binding site of poly(ADP-ribose) glycohydrolase. , 2003, Biochemistry.

[36]  N. V. van Riel,et al.  Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. , 2005, Biochemical pharmacology.

[37]  A. Gaikwad,et al.  Change in post‐translational modifications of histone H3, heat‐shock protein‐27 and MAP kinase p38 expression by curcumin in streptozotocin‐induced type I diabetic nephropathy , 2008, British journal of pharmacology.

[38]  L. Tentori,et al.  Chemopotentiation by PARP inhibitors in cancer therapy. , 2005, Pharmacological research.